Published on in Vol 21, No 10 (2019): October

Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study

Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study

Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study

Journals

  1. Gold M, Lincoln G, Cashman P, Braunack-Mayer A, Stocks N. Efficacy of m-Health for the detection of adverse events following immunization – The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial. Vaccine 2021;39(2):332 View
  2. Gold M, Lincoln G, Bednarz J, Braunack-Mayer A, Stocks N. Consumer acceptability and validity of m-Health for the detection of adverse events following immunization – The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) randomised control trial. Vaccine 2021;39(2):237 View
  3. Ohr S, Giles M, Munnoch S, Hunter M, Bolte M, Ferguson J, Deane J, Cashman P, Foureur M. What gets measured gets noticed. Tracking surgical site infection post caesarean section through community surveillance: A post intervention study protocol. Journal of Advanced Nursing 2021;77(5):2530 View
  4. Gidengil C, Goetz M, Newberry S, Maglione M, Hall O, Larkin J, Motala A, Hempel S. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine 2021;39(28):3696 View
  5. Singh G, Nesaraj R, Bchara N, Kop B, Leeb A, Nissen L, Peters I, Perry D, Salter S, Lee K. Immunisation provider experiences with an automated short message service-based active surveillance system for monitoring adverse events following immunisation: A qualitative descriptive study. DIGITAL HEALTH 2021;7:205520762110381 View
  6. Wheeler A, Garg H, Kaushik D, Mansour A, Pruthi D, Liss M. Predictors of participants’ retention—socioeconomic factors or nonadherence: insights from a urological clinical prospective study. Trials 2022;23(1) View
  7. Phillips A, Glover C, Leeb A, Cashman P, Fathima P, Crawford N, Snelling T, Durrheim D, Macartney K. Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance. BMJ Open 2021;11(3):e043880 View
  8. Asfaw M, Senbit M, Yesuf M, Dagnaw M, Birhan G, Abat A, Ibrahim S. A Preliminary Investigation on a Commercial Ovine Pasteurellosis Vaccine Using Clinical and Pathological Endpoints. Infection and Drug Resistance 2022;Volume 15:2937 View
  9. Psihogios A, Brianne Bota A, Mithani S, Greyson D, Zhu D, Fung S, Wilson S, Fell D, Top K, Bettinger J, Wilson K. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study. Vaccine 2022;40(31):4065 View
  10. Nyambayo P, Gold M, Mehta U, Clarke S, Manyevere R, Chirinda L, Zifamba E, Nyamandi T. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial. Vaccine 2023;41(45):6700 View
  11. Dias-Karunaratne N, Whop L, Ward J, Vujovich-Dunn C, Amin J, Dakiniewich A, Dyda A. Representation of marginalised populations in digital surveillance for notifiable conditions in Australia: a systematic review. Perspectives in Public Health 2024 View